Treatment of pre-menopausal advanced breast cancer with goserelin--a long-acting luteinizing hormone releasing hormone agonist.

摘要: Twenty-two pre-menopausal evaluable patients with advanced breast cancer (median age 39 years; ER positive 19, unknown three; prior adjuvant chemotherapy 16) were treated the LHRH agonist goserelin depot (Zoladex). Serum levels of 17 beta-estradiol and progesterone suppressed by within 3-4 weeks therapy, while serum leuteinizing hormone follicle stimulating titers remained in low level normal range. Complete or partial response was documented seven 22 cases (32%) occurred all major sites disease. Tumor women regularly menstruating at start therapy. Median time to disease progression 23 weeks; median duration 64 overall survival 141 weeks. Zoladex well tolerated: only hot flushes 82% reversible cutaneous pigmentation site injection 45% observed. In our experience activity comparable that oophorectomy, without psychological trauma morbidity related surgical castration.